Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Iron Protein Succinylate→

Iron Protein Succinylate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Oral iron replacement complexferric iron–protein succinylate
Mechanism of action
A ferric iron–protein succinylate complex designed to maintain iron solubility in the gastrointestinal tract and deliver iron for absorption. The protein component is digested in the small intestine, releasing iron for transferrin transport and haemoglobin synthesis.
Indications / reported uses
  • Oral treatment of iron deficiency and iron-deficiency anaemia with formulations authorised for ferric protein succinylate; elemental iron content and dosage are product-specific.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=iron+protein+succinylate+iron+deficiency · https://pubchem.ncbi.nlm.nih.gov/#query=iron%20protein%20succinylate · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Oral iron replacement complex; ferric iron–protein succinylate

Mechanism of action

A ferric iron–protein succinylate complex designed to maintain iron solubility in the gastrointestinal tract and deliver iron for absorption. The protein component is digested in the small intestine, releasing iron for transferrin transport and haemoglobin synthesis.

General use cases

  • Oral treatment of iron deficiency and iron-deficiency anaemia with formulations authorised for ferric protein succinylate; elemental iron content and dosage are product-specific.
Active moiety: ferric iron–protein succinylate complex (Related chemical form or complex; use the note below to understand the identity distinction.)

A ferric iron–protein complex; this should not be reduced to a simple iron salt without respecting the complex formulation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Iron Protein Succinylate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iron Protein Succinylate Permitted Daily Exposure (PDE) report (the Iron Protein Succinylate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iron Protein Succinylate Occupational Exposure Limit (OEL) report (the Iron Protein Succinylate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.